Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of mRNA-1283 And mRNA-1273 Variant-Containing Formulation in Adults 50 to 64 Years of Age Without Underlying Conditions That Put Them at High Risk for Severe Outcomes From COVID-19

NCT07266558 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT07266558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07266558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of mRNA-1283 And mRNA-1273 Variant-Containing Formulation in Adults 50 to 64 Years of Age Without Underlying Conditions That Put Them at High Risk for Severe Outcomes From COVID-19
Lead sponsor
ModernaTX, Inc.
Phase
Phase 4
Overall status
Active, not recruiting
Start date
November 26, 2025
Completion date
June 16, 2027
Enrollment
30,000 (actual)
Sites
150

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2